http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 02 Sep 2026 06:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VOLITIONRX+LTD++++++++++++For%3A+Aug+27/27015143.html si-local-file:///var/storage/secattach/20260902/27015143.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VOLITIONRX+LTD++++++++++++For%3A+Aug+27/27015143.html Wed, 02 Sep 2026 06:05:00 -0400 VNRX http://www.streetinsider.com/Equity+Offerings/Volitionrx+Limited+%28VNRX%29+files+for+10M+share+offering+by+selling+stockholders/26998336.html <p>Volitionrx Limited (NYSE: VNRX) filed for up to 10,006,360 share offering by selling stockholders.</p> http://www.streetinsider.com/Equity+Offerings/Volitionrx+Limited+%28VNRX%29+files+for+10M+share+offering+by+selling+stockholders/26998336.html Fri, 28 Aug 2026 16:23:31 -0400 VNRX http://www.streetinsider.com/Corporate+News/Volitionrx+Limited+%28VNRX%29+files+for+10M+share+offering+by+selling+stockholders/26998336.html <p>Volitionrx Limited (NYSE: VNRX) filed for up to 10,006,360 share offering by selling stockholders.</p> http://www.streetinsider.com/Corporate+News/Volitionrx+Limited+%28VNRX%29+files+for+10M+share+offering+by+selling+stockholders/26998336.html Fri, 28 Aug 2026 16:23:31 -0400 VNRX http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++VOLITIONRX+LTD+++++++++++++++++++++++/26998309.html si-local-file:///var/storage/secattach/20260828/26998309.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++VOLITIONRX+LTD+++++++++++++++++++++++/26998309.html Fri, 28 Aug 2026 16:21:00 -0400 O.06705185 VNRX http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++VOLITIONRX+LTD+++++++++++++++++++++++/26998309.html si-local-file:///var/storage/secattach/20260828/26998309.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++VOLITIONRX+LTD+++++++++++++++++++++++/26998309.html Fri, 28 Aug 2026 16:21:00 -0400 O.06705185 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/Press+Releases/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html <div class="xn-content"> <p class="prntac"><b><i>112% H1 Revenue Growth, Advance Toward <money>$5 Million</money> Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- VolitionRx Limited <span>(NYSE AMERICAN</span>: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.</p> <p><b>Key Highlights:</b></p><ul type="disc"><li><b>Sepsis &amp; NETosis Validation:</b> Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q^® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic http://www.streetinsider.com/PRNewswire/VolitionRx+Highlights+Commercial+Momentum+and+Multi-Pillar+Execution+Across+%2427%2B+Billion+Total+Addressable+Markets/26978270.html Wed, 26 Aug 2026 09:17:00 -0400 A.06698217 A.07309385 O.06705185 O.20043539 O.20974311 VNRX http://www.streetinsider.com/Corporate+News/Volition%27s+sepsis+biomarker+published+in+Critical+Care+Medicine/26977658.html <p>VolitionRx Limited (NYSE American: VNRX) announced the publication of a peer-reviewed study in <em>Critical Care Medicine</em> finding that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy in sepsis and septic shock patients.</p><p>The study, a secondary analysis of the SISPCT randomized controlled trial, found significantly higher H3.1 nucleosome levels in septic shock patients compared to those with sepsis, and identified a dose-response relationship with acute kidney injury severity. The authors concluded the biomarker has potential clinical utility for risk stratification and early intervention in critically ill patients.</p><p><em>Critical Care Medicine</em> also published http://www.streetinsider.com/Corporate+News/Volition%27s+sepsis+biomarker+published+in+Critical+Care+Medicine/26977658.html Wed, 26 Aug 2026 08:18:39 -0400 VNRX http://www.streetinsider.com/Press+Releases/Volition+Announces+Landmark+Clinical+Validation+of+Nu.Q%C2%AE+NETs+Biomarker+in+Sepsis/26977654.html <div class="xn-content"> <p class="prntac"><b>Published in </b><b><i>Critical Care Medicine</i></b><b>, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's <money>$2.8 billion</money> addressable market.</b></p><p><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a peer-reviewed paper and independent Editorial which reported that its Nu.Q® NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.</p> <p>Entitled "<a target="_blank" href="https://www.ovid.com/jnls/ccmjournal/fulltext/10.1097/ccm.0000000000007270~h31-nucleosomes-to-predict-renal-replacement-therapy-and" target="_blank" rel="nofollow"><b>H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in http://www.streetinsider.com/Press+Releases/Volition+Announces+Landmark+Clinical+Validation+of+Nu.Q%C2%AE+NETs+Biomarker+in+Sepsis/26977654.html Wed, 26 Aug 2026 08:17:00 -0400 O.06705185 VNRX http://www.streetinsider.com/Press+Releases/Volition+Announces+Landmark+Clinical+Validation+of+Nu.Q%C2%AE+NETs+Biomarker+in+Sepsis/26977654.html <div class="xn-content"> <p class="prntac"><b>Published in </b><b><i>Critical Care Medicine</i></b><b>, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's <money>$2.8 billion</money> addressable market.</b></p><p><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a peer-reviewed paper and independent Editorial which reported that its Nu.Q® NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.</p> <p>Entitled "<a target="_blank" href="https://www.ovid.com/jnls/ccmjournal/fulltext/10.1097/ccm.0000000000007270~h31-nucleosomes-to-predict-renal-replacement-therapy-and" target="_blank" rel="nofollow"><b>H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in http://www.streetinsider.com/Press+Releases/Volition+Announces+Landmark+Clinical+Validation+of+Nu.Q%C2%AE+NETs+Biomarker+in+Sepsis/26977654.html Wed, 26 Aug 2026 08:17:00 -0400 O.06705185 VNRX http://www.streetinsider.com/PRNewswire/Volition+Announces+Landmark+Clinical+Validation+of+Nu.Q%C2%AE+NETs+Biomarker+in+Sepsis/26977654.html <div class="xn-content"> <p class="prntac"><b>Published in </b><b><i>Critical Care Medicine</i></b><b>, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's <money>$2.8 billion</money> addressable market.</b></p><p><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a peer-reviewed paper and independent Editorial which reported that its Nu.Q® NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.</p> <p>Entitled "<a target="_blank" href="https://www.ovid.com/jnls/ccmjournal/fulltext/10.1097/ccm.0000000000007270~h31-nucleosomes-to-predict-renal-replacement-therapy-and" target="_blank" rel="nofollow"><b>H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in http://www.streetinsider.com/PRNewswire/Volition+Announces+Landmark+Clinical+Validation+of+Nu.Q%C2%AE+NETs+Biomarker+in+Sepsis/26977654.html Wed, 26 Aug 2026 08:17:00 -0400 O.06705185 VNRX http://www.streetinsider.com/PRNewswire/Volition+Announces+Landmark+Clinical+Validation+of+Nu.Q%C2%AE+NETs+Biomarker+in+Sepsis/26977654.html <div class="xn-content"> <p class="prntac"><b>Published in </b><b><i>Critical Care Medicine</i></b><b>, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's <money>$2.8 billion</money> addressable market.</b></p><p><location value="LU/us.nv.henson" idsrc="xmltag.org" >HENDERSON, Nev.</location>, <span class="legendSpanClass"><chron>Aug. 26, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:VNRX" idsrc="xmltag.org" >VolitionRx Limited</span> (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a peer-reviewed paper and independent Editorial which reported that its Nu.Q® NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.</p> <p>Entitled "<a target="_blank" href="https://www.ovid.com/jnls/ccmjournal/fulltext/10.1097/ccm.0000000000007270~h31-nucleosomes-to-predict-renal-replacement-therapy-and" target="_blank" rel="nofollow"><b>H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in http://www.streetinsider.com/PRNewswire/Volition+Announces+Landmark+Clinical+Validation+of+Nu.Q%C2%AE+NETs+Biomarker+in+Sepsis/26977654.html Wed, 26 Aug 2026 08:17:00 -0400 O.06705185 VNRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VOLITIONRX+LTD++++++++++++For%3A+Aug+19/26968970.html si-local-file:///var/storage/secattach/20260824/26968970.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VOLITIONRX+LTD++++++++++++For%3A+Aug+19/26968970.html Mon, 24 Aug 2026 17:01:00 -0400 O.06705185 VNRX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VOLITIONRX+LTD++++++++++++For%3A+Aug+19/26968970.html si-local-file:///var/storage/secattach/20260824/26968970.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++VOLITIONRX+LTD++++++++++++For%3A+Aug+19/26968970.html Mon, 24 Aug 2026 17:01:00 -0400 O.06705185 VNRX http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++VOLITIONRX+LTD+++++++++++++++++++++++/26962354.html si-local-file:///var/storage/secattach/20260821/26962354.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++VOLITIONRX+LTD+++++++++++++++++++++++/26962354.html Fri, 21 Aug 2026 17:05:00 -0400 O.06705185 VNRX